Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human AIPL1 293 Cell Lysate

Cat.No. : AIPL1-8949HCL
  • Specification
  • Gene Information
  • Related Products
Description : Antigen standard for aryl hydrocarbon receptor interacting protein-like 1 (AIPL1), transcript variant 1 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
Source : HEK 293 cells
Species : Human
Components : This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
Size : 0.1 mg
Storage Instruction : Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
Applications : ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.
Gene Name : AIPL1 aryl hydrocarbon receptor interacting protein-like 1 [ Homo sapiens ]
Official Symbol : AIPL1
Synonyms : AIPL1; aryl hydrocarbon receptor interacting protein-like 1; aryl hydrocarbon receptor interacting protein like 1 , LCA4; aryl-hydrocarbon-interacting protein-like 1; LCA4; AIPL2;
Gene ID : 23746
mRNA Refseq : NM_001033054
Protein Refseq : NP_001028226
MIM : 604392
UniProt ID : Q9NZN9
Chromosome Location : 17p13.1
Function : binding; farnesylated protein binding; unfolded protein binding;

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (19)

Ask a question
Can AIPL1-related conditions lead to other health problems apart from vision loss? 05/30/2023

AIPL1-related conditions primarily affect vision and are characterized by retinal degeneration. However, there have been reports of some individuals with AIPL1 mutations experiencing extraocular symptoms. These symptoms can include mild intellectual disability, developmental delay, hearing loss, or skeletal abnormalities. It is important to note that the severity and manifestation of these additional health problems can vary among affected individuals.

What are the symptoms of AIPL1-related conditions? 05/08/2023

The symptoms of AIPL1-related conditions, like LCA, typically manifest early in life and vary in severity. Common symptoms include severe visual impairment or blindness at birth or in infancy, abnormal eye movements, poor pupillary response, and reduced or absent retinal responses on electroretinography (ERG) testing. Some individuals may also have associated features like nystagmus (involuntary eye movements), cataracts, or hyperopia (farsightedness).

Is genetic testing available for AIPL1 mutations? 04/18/2022

Yes, genetic testing is available to identify mutations in the AIPL1 gene. This can be helpful in confirming a diagnosis of AIPL1-related conditions and allowing for genetic counseling for affected individuals and their families. Genetic testing can also assist in predicting the likelihood of passing on the mutation to future generations.

How common are AIPL1-related conditions? 05/27/2020

AIPL1-related conditions, specifically Leber congenital amaurosis (LCA) caused by AIPL1 mutations, are considered rare. The prevalence of LCA overall is estimated to be around 1 in 30,000 to 1 in 80,000 individuals in the general population, but it can vary depending on the specific population studied.

Are there any support groups or organizations for individuals with AIPL1-related conditions? 02/09/2020

Yes, there are several support groups and organizations that provide resources, information, and support for individuals and families affected by AIPL1-related conditions, specifically LCA. Some examples include the LCA Society, the Foundation Fighting Blindness, and the National Organization for Rare Disorders (NORD). These organizations offer a range of services, including peer support networks, educational materials, research updates, and access to clinical trials.

How is AIPL1-related vision loss diagnosed? 03/29/2019

AIPL1-related vision loss is typically diagnosed through a combination of clinical evaluations, family history assessment, electroretinography (ERG), and genetic testing. Clinical exams involve a thorough evaluation of visual function, including visual acuity, visual field, and fundoscopy to assess the appearance of the retina. ERG measures the electrical activity of the retina and can help identify abnormalities in the retinal function. Genetic testing involves analyzing the AIPL1 gene for mutations using techniques such as DNA sequencing.

What happens if there is a mutation in the AIPL1 gene? 01/01/2019

Mutations in the AIPL1 gene can lead to a condition called Leber congenital amaurosis (LCA), which is a severe form of inherited retinal degeneration. These mutations impair the normal function of the AIPL1 protein, resulting in abnormal protein folding and trafficking in photoreceptor cells. This ultimately leads to the degeneration of these cells and progressive vision loss.

Can AIPL1 mutations cause conditions other than LCA? 12/02/2018

AIPL1 mutations primarily cause LCA, but there have been rare reports of additional ocular conditions associated with AIPL1 gene defects, such as cone-rod dystrophy (a type of retinal degeneration) and juvenile retinitis pigmentosa (a progressive degenerative disease affecting the retinal cells).

Is there any treatment available for AIPL1-related conditions? 05/12/2018

Currently, there is no known cure for AIPL1-related conditions, including LCA. However, there are ongoing research efforts exploring potential treatments. Gene therapy is a promising approach being investigated, where a functional copy of the AIPL1 gene is delivered to the affected cells in the retina to restore proper function. Other therapeutic strategies, such as stem cell therapy and pharmacological interventions, are also being explored in preclinical and early clinical trials.

Can AIPL1-related conditions be inherited? 10/13/2017

Yes, AIPL1-related conditions are typically inherited in an autosomal recessive manner. This means that an affected individual inherits two copies of the AIPL1 gene with mutations, one from each parent who is usually a carrier. Carriers of an AIPL1 mutation usually have no or mild symptoms, but they have a 25% chance of passing on the mutated gene to each of their children. Genetic counseling is recommended for individuals or couples with a family history or a known risk of AIPL1-related conditions.

Are there any support groups or resources for AIPL1-related conditions? 07/29/2017

Yes, there are various support groups and organizations that provide information, resources, and support for individuals and families affected by AIPL1-related conditions, such as the Foundation Fighting Blindness and the LCA Network. These organizations can offer guidance, connect individuals with medical professionals and researchers, and provide a community of support for those affected by these conditions.

Are there any ongoing research studies or clinical trials related to AIPL1-related conditions? 06/15/2017

Yes, there are ongoing research studies and clinical trials focused on understanding AIPL1-related conditions and developing potential treatments. These studies may involve gene therapy, stem cell therapy, pharmacological interventions, or other innovative approaches. ClinicalTrials.gov is a useful resource to search for current clinical trials and research studies related to AIPL1 and associated conditions. Additionally, academic institutions, research organizations, and eye centers often conduct studies related to these conditions.

Can AIPL1-related conditions be treated? 04/20/2017

Currently, there is no cure for AIPL1-related conditions such as Leber congenital amaurosis. However, there are ongoing research efforts exploring potential treatments, including gene therapy and drug-based approaches. These aim to replace or restore the function of the AIPL1 protein or target other factors involved in the disease process.

Can AIPL1 mutations be detected prenatally? 02/26/2016

Yes, it is possible to detect AIPL1 mutations prenatally through prenatal genetic testing, such as chorionic villus sampling (CVS) or amniocentesis. These tests involve collecting a sample of fetal cells or amniotic fluid to analyze the DNA and identify any genetic abnormalities, including AIPL1 mutations. Prenatal testing is typically offered in cases where there is a known risk of an inherited condition based on family history or previous affected pregnancies.

How is AIPL1-related LCA diagnosed? 02/13/2016

Diagnosis of AIPL1-related LCA involves a combination of clinical examination, electroretinography (ERG) to evaluate retinal function, and genetic testing to identify AIPL1 mutations. A detailed medical history, family history, and thorough clinical evaluation, including assessments of visual acuity, visual fields, and examination of the retina, are also performed to reach an accurate diagnosis.

How common are AIPL1-related conditions? 01/30/2016

AIPL1-related conditions, such as LCA caused by AIPL1 gene mutations, are considered to be rare disorders. The exact prevalence is difficult to determine since it varies among different populations. It has been estimated that LCA affects approximately 1 in 80,000 to 100,000 live births in the general population. However, the prevalence may be higher in specific regions or communities where consanguineous marriages are more common.

What are some of the early signs and symptoms of AIPL1-related conditions? 10/03/2015

The signs and symptoms of AIPL1-related conditions, such as LCA, typically appear within the first year of life. Infants may exhibit poor visual responsiveness, including fixed or roving eye movements, nystagmus (involuntary eye movements), and severely reduced visual acuity. Other signs can include sensitivity to light (photophobia), abnormal pupillary responses, and delayed developmental milestones related to vision. These symptoms may vary among individuals, and early diagnosis is crucial for appropriate management and intervention.

Can AIPL1-related conditions be inherited? 03/11/2015

Yes, AIPL1-related conditions are generally inherited in an autosomal recessive manner. This means that both parents must carry a mutated AIPL1 gene and pass it on to their child for the condition to manifest. If both parents are carriers, each of their offspring has a 25% chance of inheriting both copies of the mutated gene and having the condition.

Does AIPL1 have any other known functions in the body? 01/18/2015

AIPL1 is primarily known for its role in the retina and its involvement in photoreceptor function. Its function outside the retina is less well understood, but studies have suggested its involvement in cellular processes like DNA repair and maintenance of genomic stability. Further research is needed to fully understand the broader functions of AIPL1 in the body.

Customer Reviews (5)

Write a review
Reviews
11/29/2020

    By leveraging the remarkable qualities of the AIPL1 protein and tapping into the manufacturer's exceptional technical support, I am confident that I will be able to solve complex experimental problems.

    06/08/2017

      With AIPL1 as my research ally, I am poised to embark on a path of discovery, unraveling the mysteries that surround this protein and advancing our understanding in my field of study.

      10/26/2016

        AIPL1 protein stands out for its exceptional quality, rendering it an ideal choice to fulfill my experimental requirements.

        09/03/2016

          Its unparalleled purity and reliability guarantee accurate and reproducible results, imparting confidence in the validity of my scientific investigations.

          02/05/2016

            In addition to its high quality, the manufacturer of the AIPL1 protein offers excellent technical support, an invaluable resource for overcoming any challenges that may arise.

            Ask a Question for All AIPL1 Products

            Required fields are marked with *

            My Review for All AIPL1 Products

            Required fields are marked with *

            0

            Inquiry Basket

            cartIcon
            logo

            FOLLOW US

            Terms and Conditions        Privacy Policy

            Copyright © 2024 Creative BioMart. All Rights Reserved.

            Contact Us

            • /

            Stay Updated on the Latest Bioscience Trends